InVivo Therapeutics Corporation
InVivo Therapeutics Corporation Files FDA Application for Human Studies for Spinal Cord Injury Treatment
Published in Medical Letter on the CDC and FDA, December 20th, 2009
CEO Frank Reynolds is confident in the company's chances of receiving approval, and is optimistic about what obtaining a regulatory green light represents for spinal cord injury research, making InVivo's technology the first treatment of its kind to progress to clinical studies.
According to the Christopher Reeve Foundation website, there are...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Canadian Medical Association Journal
Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza - University of Toronto
Availability of vaccine no guarantee public will want it - Wiley-Blackwell
Transplant infectious disease experts provide pandemic guidance - HIV/AIDS Vaccine
U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS - infoGROUP
Consumers Pay Little or No Attention to Drug Company's Advertised Risk Disclosures, Latest Under the Skin Study from ORC Guideline Finds - Natural Health Science Inc.
Study Shows Pine Bark Improves Microcirculation, Retinal Swelling and Visual Acuity In Early Diabetic Retinopathy - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
